Impaired interleukin-12 production is associated with a defective anti- tumor response in colorectal cancer

Diseases of the Colon and Rectum

Volumn 41, Issue 4, 1998, Pages 460-463

  O'Hara, Richard J ^a   Greenman, John ^a   Drew, Philip J ^a   McDonald, Alistair W ^b   Duthie, Graeme S ^a   Lee, Peter W R ^a   Monson, John R T ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

^b CASTLE HILL HOSPITAL   (United Kingdom)

Author keywords

Advanced; Colorectal cancer; Impaired; Interleukin 12

Indexed keywords

INTERLEUKIN 12;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER STAGING; CANCER SURVIVAL; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; FEMALE; HUMAN; IMMUNOREGULATION; MALE; PREOPERATIVE EVALUATION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; HUMANS; INTERLEUKIN-12; MIDDLE AGED; NEOPLASM STAGING; STATISTICS, NONPARAMETRIC;

EID: 0031953214     PISSN: 00123706     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02235759     Document Type: Article

References (17)

1. Cancer Research Campaign. Facts on cancer: factsheets 18.1-18.4. London: Cancer Research Campaign Publication, 1993.
2. Rosenberg SA, Lotze MT, Yang JC, et al. Experience with the use of high dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989;210:474-85.
3. Walder S, Wiernik P. Clinical update on the role of flurouracil and recombinant Interferon alpha-2a in the treatment of colorectal carcinoma. Semin Oncol 1990; 17:16-21.
4. Margolin KA, Rayner AA, Hawkins MJ, et al. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumours: analysis of toxicity and management guidelines. J Clin Oncol 1989;7:486-98.
5. Trinchieri G. IL-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994;84:4008-427.
6. Schmitt E, Hoehn P, Huels C, et al. T helper type 1 development of naïve CD4+ T cells requires the coordinate action of IL-12 and IFN-γ and is inhibited by TGF-β. Eur J Immunol 1994;24:793-8.
7. Hendrzak JA, Brunda MJ. Biology of disease: interleukin 12 - biologic activity, therapeutic utility and role in disease. Lab Invest 1995;72:619-37.
8. Stern AS, Magran J, Presky DH. IL-12: an integral cytokine in the immune response. Life Sci 1996;58:639-54.
9. Brunda MJ, Luistro L, Warrier RR, et al. Antitumour and anti-metastatic activity of interleukin 12 against murine tumours. J Exp Med 1993;178:1223-30.
10. Nastala CL, Edington HD, McKinney TG, et al. Recombinant IL-12 administration induces tumour regression in association with IFN-γ production. J Immunol 1994; 153:1697-706.
11. Martinotti A, Stoppacciaro A, Vagliani M, et al. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with IL-12 genes. Eur J Immunol 1995;25:137-46.
12. Hiscox S, Halleth MB, Puntis MC, Jiang WG. Inhibition of cancer cell motility and invasion by IL-12. Clin Exp Metastasis 1995;13:396-404.
13. Blanchard DK, Djeu JY. Protection of cultured human monocytes from lymphokine-activated killer mediated lysis by IFN-γ. J Immunol 1988;141:4067-73.
14. D'Andrea A, Rengaraju M, Valiante NM, et al. Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. J Exp Med 1992;176:1387-98.
15. Dukes CE. The classification of cancer of the rectum. J Pathol Bacteriol 1932;35:1489-94.
16. Wood DA, Robbins GF, Lippin C, Lum D, Stearns M. Staging cancer of the colon and rectum. Cancer 1979; 43:961-8.
17. Rook AH, Kubin M, Cassin M, et al. IL-12 reverses cytokine and immune abnormalities in Sezary syndrome. J Immunol 1995;154:1491-8.